Current and Future Use of Neuromodulation in Heart Failure

Overview

Journal Eur Heart J Suppl

Publisher Oxford University Press

Date 2022 Aug 22

PMID 35991620

Authors

David Duncker

Johann Bauersachs

Affiliations

Soon will be listed here.

Abstract

Autonomic imbalance is a common finding in heart failure (HF) with reduced ejection fraction (HFrEF). Addressing different targets within the autonomic nervous systems has been evaluated in patients with HF, including renal sympathetic denervation, vagal nerve stimulation, and baroreceptor activation therapy (BAT). Although all are pathophysiologically plausible and promising, only BAT shows sufficient evidence for implementation into clinical practice in randomized controlled trials. Baroreceptor activation therapy can be used in patients with symptomatic HFrEF despite optimal guideline-directed medication and device therapy. This article reviews the current and future use of neuromodulation in HF and provides an overview on current guideline recommendations and clinical practice.

Citing Articles

Baroreflex activation therapy in advanced heart failure: A long-term follow-up.

Wang D, Mueller-Leisse J, Hillmann H, Eiringhaus J, Berliner D, Karfoul N ESC Heart Fail. 2024; 12(1):166-173.

PMID: 39379167 PMC: 11769634. DOI: 10.1002/ehf2.15104.

Cardiac Contractility Modulation for Heart Failure: Current and Future Directions.

Pipilas D, Hanley A, Singh J, Mela T J Soc Cardiovasc Angiogr Interv. 2024; 2(6Part B):101176.

PMID: 39131075 PMC: 11307863. DOI: 10.1016/j.jscai.2023.101176.

Cardiovascular Reflexes - Vagus as the Key Player.

Herlekar S, Doyizode A, Siddangoudra S, Anupama V Curr Cardiol Rev. 2024; 20(5):e290424229476.

PMID: 38685784 PMC: 11337609. DOI: 10.2174/011573403X284831240408053528.

The proarrhythmogenic role of autonomics and emerging neuromodulation approaches to prevent sudden death in cardiac ion channelopathies.

Tonko J, Lambiase P Cardiovasc Res. 2024; 120(2):114-131.

PMID: 38195920 PMC: 10936753. DOI: 10.1093/cvr/cvae009.

Antiarrhythmic effects of baroreceptor activation therapy in chronic heart failure: a case report.

Wang D, Veltmann C, Bauersachs J, Duncker D Eur Heart J Case Rep. 2023; 7(11):ytad520.

PMID: 37954563 PMC: 10633707. DOI: 10.1093/ehjcr/ytad520.

References

Duncker D, Veltmann C . Device therapy in heart failure with reduced ejection fraction-cardiac resynchronization therapy and more. Herz. 2018; 43(5):415-422. DOI: 10.1007/s00059-018-4710-6. View

De Ferrari G, Crijns H, Borggrefe M, Milasinovic G, Smid J, Zabel M . Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J. 2010; 32(7):847-55. DOI: 10.1093/eurheartj/ehq391. View

Ahmad Y, Francis D, Bhatt D, Howard J . Renal Denervation for Hypertension: A Systematic Review and Meta-Analysis of Randomized, Blinded, Placebo-Controlled Trials. JACC Cardiovasc Interv. 2021; 14(23):2614-2624. DOI: 10.1016/j.jcin.2021.09.020. View

Abraham W, Zile M, Weaver F, Butter C, Ducharme A, Halbach M . Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. JACC Heart Fail. 2015; 3(6):487-496. DOI: 10.1016/j.jchf.2015.02.006. View

Zile M, Lindenfeld J, Weaver F, Zannad F, Galle E, Rogers T . Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2020; 76(1):1-13. DOI: 10.1016/j.jacc.2020.05.015. View

Kraai I, Vermeulen K, Luttik M, Hoekstra T, Jaarsma T, Hillege H . Preferences of heart failure patients in daily clinical practice: quality of life or longevity?. Eur J Heart Fail. 2013; 15(10):1113-21. DOI: 10.1093/eurjhf/hft071. View

De Ferrari G, Stolen C, Tuinenburg A, Wright D, Brugada J, Butter C . Long-term vagal stimulation for heart failure: Eighteen month results from the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) trial. Int J Cardiol. 2017; 244:229-234. DOI: 10.1016/j.ijcard.2017.06.036. View

Fukuta H, Goto T, Wakami K, Kamiya T, Ohte N . Effects of catheter-based renal denervation on heart failure with reduced ejection fraction: a meta-analysis of randomized controlled trials. Heart Fail Rev. 2020; 27(1):29-36. DOI: 10.1007/s10741-020-09974-4. View

Patel H, Rosen S, Hayward C, Vassiliou V, Smith G, Wage R . Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): a randomized controlled trial. Eur J Heart Fail. 2016; 18(6):703-12. DOI: 10.1002/ejhf.502. View

10.

Glikson M, Nielsen J, Kronborg M, Michowitz Y, Auricchio A, Barbash I . 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021; 42(35):3427-3520. DOI: 10.1093/eurheartj/ehab364. View

11.

Bauersachs J . Heart failure drug treatment: the fantastic four. Eur Heart J. 2021; 42(6):681-683. PMC: 7878007. DOI: 10.1093/eurheartj/ehaa1012. View

12.

Gronda E, Seravalle G, Brambilla G, Costantino G, Casini A, Alsheraei A . Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. Eur J Heart Fail. 2014; 16(9):977-83. PMC: 4237551. DOI: 10.1002/ejhf.138. View

13.

Simovic S, Providencia R, Barra S, Kircanski B, Guerra J, Conte G . The use of remote monitoring of cardiac implantable devices during the COVID-19 pandemic: an EHRA physician survey. Europace. 2021; 24(3):473-480. PMC: 8499732. DOI: 10.1093/europace/euab215. View

14.

McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Bohm M . Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With.... Eur Heart J. 2021; 42(48):4901. DOI: 10.1093/eurheartj/ehab670. View

15.

Bisognano J, Bakris G, Nadim M, Sanchez L, Kroon A, Schafer J . Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011; 58(7):765-73. DOI: 10.1016/j.jacc.2011.06.008. View

16.

Floras J, Ponikowski P . The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction. Eur Heart J. 2015; 36(30):1974-82b. PMC: 4528097. DOI: 10.1093/eurheartj/ehv087. View

17.

Feyz L, Nannan Panday R, Henneman M, Verzijlbergen F, Constantinescu A, van Dalen B . Endovascular renal sympathetic denervation to improve heart failure with reduced ejection fraction: the IMPROVE-HF-I study. Neth Heart J. 2021; 30(3):149-159. PMC: 8881518. DOI: 10.1007/s12471-021-01633-z. View

18.

Coats A, Abraham W, Zile M, Lindenfeld J, Weaver F, Fudim M . Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials. Eur J Heart Fail. 2022; 24(9):1665-1673. PMC: 9796660. DOI: 10.1002/ejhf.2573. View

19.

Yancy C, Jessup M, Bozkurt B, Butler J, Casey Jr D, Colvin M . 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society.... J Am Coll Cardiol. 2017; 70(6):776-803. DOI: 10.1016/j.jacc.2017.04.025. View

20.

Zannad F, De Ferrari G, Tuinenburg A, Wright D, Brugada J, Butter C . Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J. 2014; 36(7):425-33. PMC: 4328197. DOI: 10.1093/eurheartj/ehu345. View